TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32131901

Group type: EXPERIMENTAL
Intervention: Snoring occurring for ≥ 3 months
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Tonsillar hypertrophy
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Adenoid hypertrophy
Number of subjects: 1578
Study: 32133329

Group type: EXPERIMENTAL
Intervention: Nusinersen treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Palliative care practices
Number of subjects: 39

Group type: COMPARATOR
Intervention: Overall patient management
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 39

Group type: COMPARATOR
Intervention: Enteral nutrition
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sedative treatment
Number of subjects: 39
Study: 32134216

Group type: EXPERIMENTAL
Intervention: Dutch Leakage Score (DLS)
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Combination of positive PCT, CRP, and DLS values
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Combination of negative PCT, CRP, and DLS values
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Morbidity
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 1546
Study: 32134933

Group type: EXPERIMENTAL
Intervention: Women with POI
Number of subjects: 123
Study: 32134978

Group type: EXPERIMENTAL
Intervention: SRD5A2 promoter methylation in CRPC samples
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SRD5A2 methylation (whole promoter region)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hypermethylation of specific regions (nucleotides -434 to -4)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SRD5A2 methylation (specific region)
Number of subjects: 90
Study: 32135121

Group type: EXPERIMENTAL
Intervention: CAR T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32135566

Group type: EXPERIMENTAL
Intervention: Homozygotes for p.Thr789Ala(C)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Homozygotes for p.Thr1381Ala(C)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Homozygotes for p.Gln852Arg(C)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Homozygotes for both p.Thr789Ala(C) and p.Gln852Arg(T)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Carriers of two copies of the p.Thr1381Ala(T)/p.Gln852Arg(T) haplotype
Number of subjects: 219
Study: 32138529

Group type: EXPERIMENTAL
Intervention: MViV (mitral valve-in-valve)
Number of subjects: 903

Group type: COMPARATOR
Intervention: MViR (mitral valve-in-ring)
Number of subjects: 903

Group type: COMPARATOR
Intervention: ViMAC (valve-in-mitral annular calcification)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: All groups (MViV, MViR, ViMAC)
Number of subjects: 903
Study: 32138691

Group type: EXPERIMENTAL
Intervention: SF-12 Mental Health Score (MCS)
Number of subjects: 5022

Group type: EXPERIMENTAL
Intervention: SF-12 Physical Health Score (PCS)
Number of subjects: 5022

Group type: EXPERIMENTAL
Intervention: Subjective HRQoL
Number of subjects: 5022
Study: 32138734

Group type: EXPERIMENTAL
Intervention: Adolescents with obesity
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Adolescents with extreme obesity
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 431
Study: 32138781

Group type: EXPERIMENTAL
Intervention: ASAC-LS
Number of subjects: 17

Group type: COMPARATOR
Intervention: APAC
Number of subjects: 17
Study: 32138938

Group type: EXPERIMENTAL
Intervention: Clinician Affective Reactivity Index (CL-ARI)
Number of subjects: 98
Study: 32138941

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive-behavioral therapy (CBT)
Number of subjects: 1
Study: 32139144

Group type: EXPERIMENTAL
Intervention: Accidental awareness during general anaesthesia (AAGA) detection using three repetitions of standardised direct questioning over 30 days.
Number of subjects: 2015

Group type: EXPERIMENTAL
Intervention: Structured interviews to verify memories during general anaesthesia.
Number of subjects: 2015

Group type: EXPERIMENTAL
Intervention: Quantitative data collection on general anaesthesia conduct for all participants.
Number of subjects: 2015
Study: 32139220

Group type: EXPERIMENTAL
Intervention: Optimized thienopyridine treatment for patients with loss-of-function (LOF) alleles (class 2, n = 272)
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Wild-type genotype or gain-of-function allele (class 1, n = 1,118)
Number of subjects: 1445
Study: 32139298

Group type: EXPERIMENTAL
Intervention: Osimertinib + Selumetinib
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Osimertinib + Savolitinib
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Osimertinib + Durvalumab
Number of subjects: 77
Study: 32140080

Group type: EXPERIMENTAL
Intervention: ACT + CHMF
Number of subjects: 233

Group type: COMPARATOR
Intervention: ACT + placebo
Number of subjects: 233
Study: 32140113

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the nucleus accumbens
Number of subjects: 1
Study: 32140610

Group type: EXPERIMENTAL
Intervention: Culturally adapted Diabetes Self-Management Education intervention
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 221
Study: 32140672

Group type: EXPERIMENTAL
Intervention: MD1003 (300 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32140727

Group type: EXPERIMENTAL
Intervention: Saturated fat ingestion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lean control subjects
Number of subjects: 40
Study: 32140912

Group type: EXPERIMENTAL
Intervention: Inhaled or nasal corticosteroids
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CYP3A4 inhibitors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CYP3A4 inhibitors (specific corticosteroid: beclomethasone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal morning plasma cortisol
Number of subjects: 12
Study: 32142375

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study: 32142532

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus XELOX or mFOLFOX6 (Phase-A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI (Phase-B)
Number of subjects: 128
Study: 32142960

Group type: EXPERIMENTAL
Intervention: Nanoparticle burden in amniotic fluids
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fraction containing nanoparticles and ions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation with potential sources of exposure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall nanoparticle concentrations
Number of subjects: 100
Study: 32143580

Group type: EXPERIMENTAL
Intervention: Clinical response evaluation (CRE-1) using endoscopy with bite-on-bite biopsies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical response evaluation (CRE-2) using PET-CT, endoscopy with bite-on-bite biopsies, and EUS with fine-needle aspiration (FNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of major locoregional residual disease (> 10% residual carcinoma or any residual nodal disease)
Number of subjects: 0
Study: 32143585

Group type: EXPERIMENTAL
Intervention: Furosemide stress test (FST)
Number of subjects: 84
Study: 32143664

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy at 20, 40, and 60 L/min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline (conventional oxygen therapy)
Number of subjects: 24
Study: 32143777

Group type: EXPERIMENTAL
Intervention: Participatory art-based activity at the MMFA (2.3 h once a week for 12 weeks)
Number of subjects: 130
Study: 32143921

Group type: EXPERIMENTAL
Intervention: ACHD patients
Number of subjects: 67

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: ACHD patients with cerebral abnormalities
Number of subjects: 67
Study: 32144134

Group type: EXPERIMENTAL
Intervention: Utomilumab (0.03-10.0 mg/kg every 4 weeks) plus Rituximab (375 mg/m2)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Utomilumab plus Rituximab
Number of subjects: 67
Study: 32145771

Group type: EXPERIMENTAL
Intervention: Enasidenib (60-300 mg per day, oral, in repeated 28-day treatment cycles)
Number of subjects: 17
Study: 32146304

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg orally twice daily
Number of subjects: 44
Study: 32146703

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES) treatment
Number of subjects: 62
Study: 32147213

Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg/ml followed by electroporation (six pulses, 1500 V/cm) on days 1, 5, and 8 every 90 days
Number of subjects: 46
Study: 32147669

Group type: EXPERIMENTAL
Intervention: Dacomitinib (15 mg) plus PD-0325901 (6 mg)
Number of subjects: 41
Study: 32147671

Group type: EXPERIMENTAL
Intervention: Buparlisib (80 mg) in combination with imatinib (400 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (standard therapies)
Number of subjects: 60
Study: 32147973

Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) of sgACC-DLPFC
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) of pgACC-DLPFC
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clinical efficacy associated with DLPFC-sgACC functional connectivity
Number of subjects: 88
Study: 32148099

Group type: EXPERIMENTAL
Intervention: Perceived Stress
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Depressive Symptoms in Patients
Number of subjects: 162

Group type: COMPARATOR
Intervention: Decisional Conflict Scale
Number of subjects: 162
Study: 32148332

Group type: EXPERIMENTAL
Intervention: Two-point discrimination threshold (TPDT) over the affected shoulder of patients with FS
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Left/right judgment task (LRJT) performance in patients with FS
Number of subjects: 38

Group type: COMPARATOR
Intervention: TPDT and LRJT performance in patients with FS compared to healthy controls
Number of subjects: 38
Study: 32149736

Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study: 32149760

Group type: EXPERIMENTAL
Intervention: No-reflow group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Before nicorandil medication
Number of subjects: 59
Study: 32150040

Group type: EXPERIMENTAL
Intervention: Robot-assisted hysterectomy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Open laparotomy technique
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 18
Study: 32150070

Group type: EXPERIMENTAL
Intervention: Histopathological evaluation of unallocated pancreas organs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Macroscopic assessment by transplant surgeons
Number of subjects: 100
Study: 32150314

Group type: EXPERIMENTAL
Intervention: Quality of life assessed by Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Maximal aerobic capacity (peak oxygen consumption)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Submaximal exercise capacity (6-min walk distance)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Volume of daily activity (accelerometry)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Physician-estimated functional class
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Resting echocardiography
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Plasma natriuretic peptide levels
Number of subjects: 408
Study: 32151245

Group type: EXPERIMENTAL
Intervention: TELSA programme (Type 1 Diabetes Education in Lifestyle and Self Adjustment)
Number of subjects: 13000
Study: 32151247

Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic agents with a blood glucose cut-off value of 3.9 mmol/L (70 mg/dL)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic agents with a blood glucose cut-off value of 3.0 mmol/L (54 mg/dL)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sulfonylurea therapy
Number of subjects: 94
Study: 32151332

Group type: EXPERIMENTAL
Intervention: Carbapenemase-producing Enterobacterales
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Non-carbapenemase-producing Enterobacterales
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Unconfirmed CRE
Number of subjects: 1040
Study: 32151790

Group type: EXPERIMENTAL
Intervention: IOERT (11.1 Gy) followed by HWBI (40.5 Gy in 15 fractions)
Number of subjects: 583
Study: 32152017

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 3082

Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 3082
Study: 32152153

Group type: EXPERIMENTAL
Intervention: Asthma shared decision-making (SDM) intervention
Number of subjects: 10
Study: 32152160

Group type: EXPERIMENTAL
Intervention: Early biomarkers (albuminuria, N-acetyl-beta-D-glucosaminidase, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predisposition biomarkers (GM2AP, transferrin, t-gelsolin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study: 32152168

Group type: EXPERIMENTAL
Intervention: French-LARS score (adapted LARS scale)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: French-LARS score
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Test-retest procedure
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Risk factor analysis
Number of subjects: 1000
Study: 32152172

Group type: EXPERIMENTAL
Intervention: CHW-led intervention for diabetes
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: CHW-led intervention for hypertension
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: CHW-led intervention for diabetic patients with HbA1c ≥9%
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: CHW-led intervention for patients with uncontrolled hypertension
Number of subjects: 149
Study: 32152173

Group type: EXPERIMENTAL
Intervention: Single-dose intravenous 12/12 human leucocyte antigen-matched sibling cord blood cell infusion
Number of subjects: 12
Study: 32152221

Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells (1×10e6 CAR-T/kg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Number of subjects: 93
Study: 32152628

Group type: EXPERIMENTAL
Intervention: Plexiform neurofibromas (PNs)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Distinct nodular lesions (DNLs)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both PNs and DNLs
Number of subjects: 122
Study: 32152818

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol; Esperoct)
Number of subjects: 0
Study: 32152956

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 262
Study: 32153210

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32153439

Group type: EXPERIMENTAL
Intervention: Intense manualized treatment for 1 month as part of the ROCKETLAUNCH project
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard treatment in Sweden (data from the 10 previous patients at each outpatient clinic)
Number of subjects: 150
Study: 32153780

Group type: EXPERIMENTAL
Intervention: TLR7/8-matured dendritic cells (DCs) transfected with RNA encoding WT1, PRAME, and CMVpp65, vaccinated 10 times over 26 weeks.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TLR7/8-matured dendritic cells (DCs)
Number of subjects: 10
Study: 32153804

Group type: EXPERIMENTAL
Intervention: B-vitamins concentrations in human milk
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Regional and socioeconomic factors, lactation stage, and supplement intake
Number of subjects: 443
Study: 32153805

Group type: EXPERIMENTAL
Intervention: Pulse-based diet for 16 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: National Cholesterol Education Program therapeutic lifestyle changes (TLC) diet for 16 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups participating in an aerobic exercise program
Number of subjects: 100
Study: 32153817

Group type: EXPERIMENTAL
Intervention: DDU-supplement (500 mg DHA, 10 μg vitamin D)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 32153825

Group type: EXPERIMENTAL
Intervention: Wild blueberry juice for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32153828

Group type: EXPERIMENTAL
Intervention: WIC Fresh Start (WFS) lesson
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32153829

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dietary protein increase
Number of subjects: 27
Study: 32153840

Group type: EXPERIMENTAL
Intervention: Integrated Nutrition Pathway for Acute Care (INPAC) activities
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Screened patients at risk for malnutrition
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Patients at risk for malnutrition who did not receive a dietitian assessment
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Patients not screened at risk who were assessed
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Barriers to food intake noted in patient medical charts
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Patients provided medication for nausea as a barrier removal strategy
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Advanced nutrition care strategies recorded
Number of subjects: 700
Study: 32153856

Group type: EXPERIMENTAL
Intervention: Practical fitness, dietary, and emotional challenges introduced in the study.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual dietary intake and physical activity evaluation across strata.
Number of subjects: 0
Study: 32153857

Group type: EXPERIMENTAL
Intervention: Regular texture menus
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pureed texture menus
Number of subjects: 32
Study: 32153871

Group type: EXPERIMENTAL
Intervention: Cod intake twice weekly for 16 weeks (pregnancy week 20-36)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Habitual diet (control group)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cod intake
Number of subjects: 137
Study: 32153879

Group type: EXPERIMENTAL
Intervention: Improved supplementary food plus five anti-infective interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (3.5 kg corn/soy blended flour with 350 mL vegetable oil every two weeks)
Number of subjects: 0
Study: 32153880

Group type: EXPERIMENTAL
Intervention: 8-week intervention to reduce sedentary behavior and cardiovascular disease risk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary Behavior (SB) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle Behavior (LB) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall dietary quality
Number of subjects: 0
Study: 32153890

Group type: EXPERIMENTAL
Intervention: Integrated homestead food production, food consumption, and women's empowerment interventions delivered by community health workers and agriculture extension workers through home visits and farmer field schools.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 0
Study: 32153896

Group type: EXPERIMENTAL
Intervention: Routine amoxicillin
Number of subjects: 2412

Group type: EXPERIMENTAL
Intervention: Ready to use therapeutic food (RUTF) and standard clinical care
Number of subjects: 2412

Group type: EXPERIMENTAL
Intervention: Dietary diversity assessment
Number of subjects: 2412
Study: 32153900

Group type: EXPERIMENTAL
Intervention: Daily preventive zinc dispersible tablet
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Daily preventive multiple micronutrient powder
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Therapeutic zinc dispersible tablet for diarrhea
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 3400
Study: 32153903

Group type: EXPERIMENTAL
Intervention: semi-quantitative food frequency questionnaire (sqFFQ)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 2-day weighed food record
Number of subjects: 91
Study: 32153909

Group type: EXPERIMENTAL
Intervention: Pylopass supplementation for 28 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 32153916

Group type: EXPERIMENTAL
Intervention: High-PUFA diet
Number of subjects: 26
Study: 32153925

Group type: EXPERIMENTAL
Intervention: Low-FODMAP rye bread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular rye bread
Number of subjects: 0
Study: 32153935

Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI) strategy implementation
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Health worker practices
Number of subjects: 514
Study: 32153939

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables vouchers over one year
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nutritional education workshops
Number of subjects: 91
Study: 32153947

Group type: EXPERIMENTAL
Intervention: 40 g lipid-based nutrient supplement (Epi-E)
Number of subjects: 0
Study: 32153951

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI-2010) dietary assessment
Number of subjects: 1745
Study: 32153957

Group type: EXPERIMENTAL
Intervention: Mealworms for 2 months post-surgery
Number of subjects: 168

Group type: COMPARATOR
Intervention: Grain powder for 2 months post-surgery
Number of subjects: 168
Study: 32153959

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (30,000 IU weekly for 6 months)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 132
Study: 32153971

Group type: EXPERIMENTAL
Intervention: 12-week nutrition and physical activity program including education, coping skills training, and home-based intervention
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 294